2022
AMACR Expression is a Potential Diagnostic Marker in Apocrine Lesions of Breast, and is Associated with High Histologic Grade and Lymph Node Metastases in Some Invasive Apocrine Breast Cancers
Lerner G, Tang H, Singh K, Golestani R, St Claire S, Humphrey P, Lannin D, Janostiak R, Harigopal M. AMACR Expression is a Potential Diagnostic Marker in Apocrine Lesions of Breast, and is Associated with High Histologic Grade and Lymph Node Metastases in Some Invasive Apocrine Breast Cancers. Clinical Breast Cancer 2022, 23: 199-210. PMID: 36577560, DOI: 10.1016/j.clbc.2022.11.012.Peer-Reviewed Original ResearchConceptsInvasive ductal carcinomaTriple-negative breast cancerHigh histologic gradeApocrine differentiationAMACR expressionEstrogen receptorApocrine DCISER-/PRHistologic gradeProgesterone receptorApocrine featuresBreast cancerHuman epidermal growth factor 2 (HER2) statusLack of ERDistant metastasis-free survivalDiagnostic markerInitial N stageLack estrogen receptorApocrine breast cancerLymph node metastasisNegative breast cancerAndrogen receptor mRNACoA racemase expressionBenign breast tissueBreast cancer cohort
2017
Association of LN Evaluation with Survival in Women Aged 70 Years or Older With Clinically Node-Negative Hormone Receptor Positive Breast Cancer
Chagpar AB, Hatzis C, Pusztai L, DiGiovanna MP, Moran M, Mougalian S, Sanft T, Evans S, Hofstatter E, Wilson LD, Lannin DR. Association of LN Evaluation with Survival in Women Aged 70 Years or Older With Clinically Node-Negative Hormone Receptor Positive Breast Cancer. Annals Of Surgical Oncology 2017, 24: 3073-3081. PMID: 28766195, DOI: 10.1245/s10434-017-5936-x.Peer-Reviewed Original ResearchConceptsBreast cancer-specific survivalLN evaluationPositive breast cancerOverall survivalBreast cancerHormone receptor-positive breast cancerWomen Aged 70 YearsReceptor-positive breast cancerLymph node evaluationCancer-specific survivalLower hazard rateLN surgeryBetter OSPatient ageSEER databasePatient selectionTumor characteristicsSEER dataPatientsNode evaluationHormone receptorsCancerSurvivalTreatment variablesNCDB